ACAD

ACADIA Pharmaceuticals Inc. NASDAQ

Healthcare ·Biotechnology ·US · acadia-pharm.com

$22.19

Mkt Cap $3.8B

52w Low $14.45 55.7% of range 52w High $28.35

50d MA $22.19 200d MA $23.75

P/E (TTM) 9.5x

EV/EBITDA 31.7x

P/B 3.0x

Debt/Equity 0.0x

ROE 31.9%

P/FCF 43.0x

RSI (14) —

ATR (14) —

Beta 0.83

50d MA $22.19

200d MA $23.75

Avg Volume 2.1M

About

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 developm…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 25, 2026	AMC	0.14	1.60	+1067.9%	24.97	-5.3%	-1.3%	-1.6%	-8.7%	-9.9%	-6.3%	-16.9%	—
Nov 5, 2025	AMC	0.14	0.26	+85.7%	22.33	+5.6%	-3.0%	+1.1%	-0.6%	+6.2%	+8.1%	+22.9%	—
Aug 6, 2025	AMC	0.14	0.16	+14.3%	23.80	+1.1%	+2.5%	+3.4%	+4.3%	+6.9%	+5.6%	+6.1%	—
May 7, 2025	AMC	0.10	0.11	+10.0%	14.81	-0.6%	+14.3%	+17.8%	+18.3%	+16.1%	+15.9%	+48.4%	—
Feb 26, 2025	AMC	0.13	0.17	+30.8%	19.00	+2.3%	+1.8%	+3.2%	-4.4%	-3.9%	-4.8%	-10.2%	—
Nov 6, 2024	AMC	0.14	0.20	+42.9%	15.79	-0.6%	+8.9%	+11.8%	+15.7%	+13.6%	+11.4%	+9.4%	—
Aug 6, 2024	AMC	0.18	0.20	+11.1%	18.85	-18.3%	-19.5%	-16.6%	-17.1%	-18.9%	-16.6%	-14.0%	—
May 8, 2024	AMC	0.05	0.10	+100.0%	17.13	+2.2%	-11.2%	-11.0%	-11.4%	-13.3%	-11.7%	-13.1%	—
Feb 27, 2024	AMC	0.30	0.28	-6.7%	26.36	-6.5%	-9.9%	-11.8%	-8.9%	-9.9%	-9.7%	-29.9%	—
Nov 2, 2023	AMC	-0.43	-0.40	+7.0%	22.99	+4.4%	+4.7%	+4.3%	+2.2%	+0.9%	-4.3%	-0.6%	—
Aug 2, 2023	AMC	-0.12	0.01	+108.3%	29.20	-4.2%	-6.8%	-6.9%	-8.2%	-8.5%	-8.9%	-4.8%	—
May 8, 2023	AMC	-0.21	-0.27	-28.6%	21.55	+0.2%	-0.6%	+0.5%	-1.0%	-0.4%	+2.6%	+14.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 25	BofA Securities	Upgrade	Neutral → Buy	—	$20.96	$21.40	+2.1%	+5.0%	+2.4%	-1.0%	+0.5%	+6.2%
Mar 4	JP Morgan	Maintains	Overweight → Overweight	—	$22.50	$23.05	+2.4%	+4.0%	-0.4%	-1.5%	+0.4%	+0.2%
Feb 26	TD Cowen	Maintains	Buy → Buy	—	$24.97	$23.64	-5.3%	-1.3%	-1.6%	-8.7%	-9.9%	-6.3%
Feb 26	Citizens	Maintains	Market Outperform → Market Outperform	—	$24.97	$23.64	-5.3%	-1.3%	-1.6%	-8.7%	-9.9%	-6.3%
Feb 26	Stifel	Maintains	Hold → Hold	—	$24.97	$23.64	-5.3%	-1.3%	-1.6%	-8.7%	-9.9%	-6.3%
Feb 26	RBC Capital	Maintains	Outperform → Outperform	—	$24.97	$23.64	-5.3%	-1.3%	-1.6%	-8.7%	-9.9%	-6.3%
Feb 23	Mizuho	Upgrade	Neutral → Outperform	—	$23.99	$24.78	+3.3%	+3.1%	+2.5%	+4.1%	+2.7%	+2.4%
Feb 6	Oppenheimer	Maintains	Perform → Perform	—	$23.46	$24.04	+2.5%	+0.4%	-1.0%	-3.2%	-4.2%	-7.9%
Feb 3	RBC Capital	Maintains	Outperform → Outperform	—	$26.13	$25.69	-1.7%	-5.2%	-7.3%	-10.2%	-9.8%	-11.1%
Feb 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.13	$25.69	-1.7%	-5.2%	-7.3%	-10.2%	-9.8%	-11.1%
Feb 3	Citizens	Maintains	Market Outperform → Market Outperform	—	$26.13	$25.69	-1.7%	-5.2%	-7.3%	-10.2%	-9.8%	-11.1%
Jan 6	UBS	Maintains	Buy → Buy	—	$26.15	$26.50	+1.3%	+3.0%	+4.9%	+2.9%	+2.4%	+1.7%
Jan 6	Citigroup	Maintains	Buy → Buy	—	$26.15	$26.50	+1.3%	+3.0%	+4.9%	+2.9%	+2.4%	+1.7%
Dec 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$27.15	$27.18	+0.1%	+0.4%	-1.3%	-0.8%	-2.0%	+0.0%
Dec 11	Stifel	Maintains	Hold → Hold	—	$26.81	$26.67	-0.5%	-0.5%	+1.3%	+1.7%	-0.0%	+0.4%
Dec 2	Mizuho	Maintains	Neutral → Neutral	—	$24.85	$25.24	+1.6%	+2.3%	+4.1%	+6.8%	+10.4%	+7.7%
Nov 17	JP Morgan	Maintains	Overweight → Overweight	—	$24.02	$23.65	-1.5%	-0.0%	-0.9%	-3.8%	-4.7%	-1.9%
Nov 6	RBC Capital	Maintains	Outperform → Outperform	—	$22.33	$23.58	+5.6%	-3.0%	+1.1%	-0.6%	+6.2%	+8.1%
Nov 6	Needham	Maintains	Buy → Buy	—	$22.33	$23.58	+5.6%	-3.0%	+1.1%	-0.6%	+6.2%	+8.1%
Sep 29	JP Morgan	Maintains	Overweight → Overweight	—	$21.05	$21.27	+1.0%	+1.3%	+1.4%	+0.9%	+1.6%	+3.6%
Sep 24	Needham	Maintains	Buy → Buy	—	$23.60	$20.82	-11.8%	-9.9%	-10.1%	-10.8%	-9.7%	-9.6%
Sep 11	TD Cowen	Maintains	Buy → Buy	—	$23.80	$24.16	+1.5%	+1.7%	-0.8%	+3.7%	+0.7%	+1.7%
Sep 9	UBS	Maintains	Buy → Buy	—	$25.39	$25.54	+0.6%	-2.2%	-6.3%	-4.7%	-7.0%	-2.8%
Aug 8	UBS	Maintains	Buy → Buy	—	$24.40	$24.40	+0.0%	+0.8%	+1.7%	+4.3%	+3.0%	+0.5%
Aug 7	RBC Capital	Maintains	Outperform → Outperform	—	$23.80	$24.06	+1.1%	+2.5%	+3.4%	+4.3%	+6.9%	+5.6%
Aug 7	Goldman Sachs	Maintains	Sell → Sell	—	$23.80	$24.06	+1.1%	+2.5%	+3.4%	+4.3%	+6.9%	+5.6%
Aug 7	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$23.80	$24.06	+1.1%	+2.5%	+3.4%	+4.3%	+6.9%	+5.6%
Aug 7	BofA Securities	Maintains	Neutral → Neutral	—	$23.80	$24.06	+1.1%	+2.5%	+3.4%	+4.3%	+6.9%	+5.6%
Aug 7	Mizuho	Maintains	Neutral → Neutral	—	$23.80	$24.06	+1.1%	+2.5%	+3.4%	+4.3%	+6.9%	+5.6%
Jul 24	JP Morgan	Maintains	Overweight → Overweight	—	$23.27	$23.00	-1.2%	-0.9%	-0.1%	-2.8%	-2.8%	+1.1%
Jun 27	UBS	Maintains	Buy → Buy	—	$22.21	$22.18	-0.1%	-0.4%	-2.9%	-3.8%	-4.4%	-5.7%
Jun 26	Oppenheimer	Maintains	Perform → Perform	—	$22.50	$22.56	+0.3%	-1.3%	-1.7%	-4.1%	-5.1%	-5.6%
Jun 26	Needham	Maintains	Buy → Buy	—	$22.50	$22.56	+0.3%	-1.3%	-1.7%	-4.1%	-5.1%	-5.6%
Jun 26	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$22.50	$22.56	+0.3%	-1.3%	-1.7%	-4.1%	-5.1%	-5.6%
Jun 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.50	$22.56	+0.3%	-1.3%	-1.7%	-4.1%	-5.1%	-5.6%
Jun 23	RBC Capital	Maintains	Outperform → Outperform	—	$22.71	$23.04	+1.5%	-1.0%	-1.3%	-0.9%	-2.2%	-2.6%
Jun 6	JP Morgan	Maintains	Overweight → Overweight	—	$21.34	$21.53	+0.9%	+3.0%	+4.5%	+4.0%	+4.5%	+1.9%
Jun 5	BofA Securities	Maintains	Neutral → Neutral	—	$21.77	$21.61	-0.7%	-2.0%	+1.0%	+2.4%	+2.0%	+2.4%
May 21	Deutsche Bank	Upgrade	Hold → Buy	—	$21.69	$22.24	+2.5%	+0.7%	-0.6%	+1.3%	+2.3%	+1.5%
May 20	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$21.99	$21.85	-0.6%	-1.4%	-0.6%	-2.0%	-0.0%	+0.9%
May 19	RBC Capital	Maintains	Outperform → Outperform	—	$22.26	$22.30	+0.2%	-1.2%	-2.6%	-1.8%	-3.2%	-1.3%
May 19	BMO Capital	Maintains	Outperform → Outperform	—	$22.26	$22.30	+0.2%	-1.2%	-2.6%	-1.8%	-3.2%	-1.3%
May 19	Needham	Maintains	Buy → Buy	—	$22.26	$22.30	+0.2%	-1.2%	-2.6%	-1.8%	-3.2%	-1.3%
May 19	Mizuho	Maintains	Neutral → Neutral	—	$22.26	$22.30	+0.2%	-1.2%	-2.6%	-1.8%	-3.2%	-1.3%
May 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.26	$22.30	+0.2%	-1.2%	-2.6%	-1.8%	-3.2%	-1.3%
May 19	Baird	Maintains	Outperform → Outperform	—	$22.26	$22.30	+0.2%	-1.2%	-2.6%	-1.8%	-3.2%	-1.3%
May 16	JP Morgan	Maintains	Overweight → Overweight	—	$17.60	$18.37	+4.4%	+26.5%	+24.9%	+23.2%	+24.1%	+22.4%
May 8	Deutsche Bank	Maintains	Hold → Hold	—	$14.81	$14.72	-0.6%	+14.3%	+17.8%	+18.3%	+16.1%	+15.9%
Apr 28	UBS	Maintains	Buy → Buy	—	$14.73	$14.80	+0.5%	-0.5%	-2.0%	-0.9%	-1.1%	+1.2%
Apr 17	BMO Capital	Maintains	Outperform → Outperform	—	$14.57	$14.47	-0.7%	+1.1%	-1.3%	-1.5%	+0.3%	+1.8%

Recent Filings

8-K · 5.02 !!! Very High

ACADIA Pharmaceuticals Inc. -- 8-K 5.02: Executive Change

ACADIA Pharmaceuticals appointed Thompson as a director, potentially signaling new leadership perspective and governance strengthening for the biopharmaceutical company's board oversight.

May 1

8-K · 5.02 !!! Very High

Acadia Pharmaceuticals Inc. -- 8-K 5.02: Executive Change

Jonathan M. Poole has joined Acadia Pharmaceuticals' board as a Class II director, expanding the company's governance structure and potentially bringing new expertise to guide strategic decisions.

Mar 5

8-K

Acadia Pharmaceuticals Inc. -- 8-K Filing

Acadia Pharmaceuticals surpassed $1 billion in annual revenue for the first time in 2025, demonstrating strong operational growth and market success across its pharmaceutical portfolio.

Feb 25

Data updated apr 24, 2026 10:23am · Source: massive.com